Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer

To assess the changes in estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 expression in breast cancer patients after various neoadjuvant chemotherapies. Data from 138 locally advanced breast cancer patients with histological diagnoses were...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical and experimental pathology 2015, Vol.8 (1), p.914-921
Main Authors: Jin, Guangchao, Han, Yu, Liu, Cun, Chen, Liansheng, Ding, Butong, Xuan, Shijin, Liu, Xianqiang, Ma, Guohui, Gao, Jun, Tian, Xingsong
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - analysis
Breast Neoplasms - drug therapy
Carcinoma - drug therapy
Cyclophosphamide - administration & dosage
Doxorubicin - administration & dosage
Doxorubicin - analogs & derivatives
Female
Humans
Ki-67 Antigen - analysis
Ki-67 Antigen - biosynthesis
Ki-67 Antigen - drug effects
Middle Aged
Neoadjuvant Therapy
Original
Receptor, ErbB-2 - analysis
Receptor, ErbB-2 - biosynthesis
Receptor, ErbB-2 - drug effects
Receptors, Estrogen - analysis
Receptors, Estrogen - biosynthesis
Receptors, Estrogen - drug effects
Receptors, Progesterone - analysis
Receptors, Progesterone - biosynthesis
Receptors, Progesterone - drug effects
Taxoids - administration & dosage
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the changes in estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 expression in breast cancer patients after various neoadjuvant chemotherapies. Data from 138 locally advanced breast cancer patients with histological diagnoses were reviewed. Seventy patients (group 1) were given 4 cycles of 500 mg/m(2) cyclophosphamide and 50 mg/m(2) pirarubicin every 21 days. Sixty-eight patients (group 2) were given 4 cycles of 500 mg/m(2) cyclophosphamide and 75 mg/m(2) docetaxel every 21 days. The biomarker changes of the operated tumor tissues were compared with the initial core biopsies. ER, PR, HER2 and Ki-67 expression changed by 28.6%, 22.9%, 17.1% and 54.3%, respectively, after neoadjuvant chemotherapy in group 1 and 16.2%, 22.1%, 13.2% and 70.6%, respectively, after neoadjuvant chemotherapy in group 2. There were significant differences between the groups regarding ER and Ki-67 status changes, and these changes can be used to inform treatment strategies.
ISSN:1936-2625